

PainChek receives regulatory clearance from Health Canada

HIGHLIGHTS

- Regulatory clearance received from Health Canada, allowing PainChek to enter the Canadian market and build on its partnership with AlayaCare Canada for the Home Care market.
- Active selling to clients in Canada expected to commence in the next quarter.
- Approval also allows PainChek to extend into aged care and hospitals in Canada
- Canada represents a \$5 billion¹ market for in-home health and support services
- PainChek is partnered with AlayaCare to provide lead generation and marketing support in Australia and Canada

PainChek[®] Ltd (ASX: PCK) (“PainChek[®]” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to announce it has received regulatory clearance from Health Canada, allowing it to move into the \$5 billion¹ in-home health and support services market in the country.

Health Canada issued PainChek a license in accordance with its Medical Devices Regulations of the Food and Drugs Act for the Manufacture of Class I Devices for Distribution.

The regulatory clearance follows the Company’s recent announcement extending its relationship with Montreal-based home health care software provider AlayaCare (ASX Announcement 28 October 2020). The two companies are already working together in Australia.

With the regulatory clearance received, AlayaCare will provide lead generation and marketing support to PainChek in the Canadian market, with PainChek overseeing direct sales, implementation, training and technical support to customer’s in the region. AlayaCare will receive fees from PainChek for integration of the PainChek technology into their home care software platform in line with the Australian market agreement.

Active selling to clients in the Canadian market was expected to commence in the next quarter.

PainChek[®] CEO Philip Daffas said:

“We are really pleased to have secured this approval from Health Canada, as it allows us to grow into the sizeable Canadian market with the help of our partner AlayaCare, but also move into aged care services and hospitals in Canada.”

¹ <https://www150.statcan.gc.ca/n1/daily-quotidien/190731/dq190731c-eng.htm>

The Canadian market presents another sizeable market opportunity for PainChek, having grown to more than \$5 billion² in annual operating revenue for home support services and home health care services as the population both ages and veers away from long-term residential care facilities. It is estimated that 1 million³ Canadians are receiving care in a home or community-based setting, while there are an estimated 500,000 Canadians living with dementia.

As well as North America and the UK, PainChek is also expanding into the New Zealand residential aged care market, following its recent announcement of a partnership with leading New Zealand medication management system, Medi-map Medication Management.

About AlayaCare

AlayaCare is a provider of revolutionary cloud-based home health care software which serves 500 global clients. It has an end-to-end solution spanning clinical documentation, back office functionality, client and family portals, remote patient monitoring, and mobile care worker functionality. It is focused on innovation and delivering home care of the future.

This release has been authorized for release by CEO Philip Daffas.

For more information:

Ian Hobson
Company Secretary, PainChek
ian.hobson@painchek.com
+61 8 9388 8290

Philip Daffas
CEO, PainChek
philip.daffas@painchek.com
0406 537 235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com

² <https://www150.statcan.gc.ca/n1/daily-quotidien/190731/dq190731c-eng.htm>

³ <https://www150.statcan.gc.ca/n1/pub/82-003-x/2018009/article/00001-eng.htm>